SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs quarterly earnings beat expectations and its raised outlook, powered by rapid commercial AI growth that surpassed U.S. government revenue for the first time, are driving discussion. Bulls point to strong execution, while bears argue the growth was already priced in and the stocks weak reaction reflects its high valuation and broader tech-market pressure.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples quarterly earnings beat estimates, but shares sold off as traders focused on margin pressure from rising memory costs, slower growth guidance, and weaker China, iPad, and wearables results. The community is split between buyers pointing to strong iPhone sales and bulls arguing the drop is an overreaction, and skeptics concerned about valuation and the outlook.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reached its prespecified 80th event, triggering final analysis and putting the pending GPS topline results in focus. The stocks sharp decline since the milestone has fueled debate over profit-taking and risk reduction ahead of a binary readout versus unsubstantiated claims of manipulation or a data leak; no results have been disclosed.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock agreement to acquire Lumentum is driving attention, with traders criticizing the dilution, price and long closing timeline as the stock sells off. Others argue the deal strengthens Marvells position in AI data-center optical connectivity and could pay off over the longer term.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned equity and debt fundraising for its AI infrastructure buildout has driven the selloff, with traders worried about shareholder dilution, rising leverage, and whether AI spending will pay off. Others argue the financing was already outlined and see the sharp reaction as an overreaction or a buying opportunity.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly earnings report is the focus after a sharp selloff in the shares and broader semiconductor weakness following Intels warning. Traders are divided on whether AI-chip demand and forward guidance can restore confidence or whether high valuation and the recent tech-sector pressure will weigh on the stock despite a strong report.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Small-cap rotation and IWMs relative strength against pressured megacap technology stocks dominate the discussion, with traders debating whether the rebound signals a sustained recovery or a temporary bounce. Bulls point to improving small-cap momentum and seasonal optimism, while bears cite choppy trading and uncertainty around interest rates, elections, and geopolitical risks.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA drew attention as the Dow held up better than tech-heavy indexes amid concern over AI spending and valuations, with traders debating whether the markets bounce could last and many continuing to favor shorts. Lower oil on hopes for U.S.-Iran diplomacy also featured in the broader market discussion.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells announced all-stock acquisition of Lumentum is driving attention, with LITE shares plunging as traders focus on the fixed exchange ratio, exposure to Marvells falling share price, and the long wait for closing. Many criticize the deal as unfavorable to LITE shareholders and question whether it will be approved, while others see the selloff as an overreaction and point to the companies AI-optics strategic fit.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergents Q3 results and reduced full-year outlook are driving discussion, with traders focused on weak revenue, declining NARCAN sales and delayed or uncertain government orders. Bears question the turnaround and debt outlook, while bulls point to cost cuts and potential future CYFENDUS replenishment as offsets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Momentum Stock to Buy for November 2nd

ENTG, CNXN and BLCO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 2, 2026.

Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

New Strong Buy Stocks for November 2nd

YPF, PBR, BLCO, LFUS and VRT have been added to the Zacks Rank #1 (Strong Buy) List on November 2, 2026.

Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of results from a multinational survey examining symptoms, interactions with health care professionals (HCPs) and treatment...

Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Bausch & Lomb Q3 2026 Earnings Call Transcript

Bausch & Lomb (TSX:BLCO) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

Bausch + Lomb Swings To Profit In Q3, Lifts FY26 Guidance; Pre-market Shares Up

(RTTNews) - Bausch + Lomb Corp. (BLCO), a global eye health company, on Wednesday announced a return to profit for the third quarter of fiscal 2026, as revenue increased across all three business segments. The company also raised its full-year revenue and adjusted EBITDA guidance...

Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +61.91% and +0.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2026 financial results. Our third-quarter performance reflects the strength and breadth of the business, with growth across all...

Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up

Dan Loeb's Third Point acquired approximately 85,000 Bausch + Lomb shares worth about $1.4 million as of June 30, according to the filing.read more...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Bausch + Lomb Corp

BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant version of the same drug candidate for geographic atrophy.&nbsp;</li><li>Clinical trials for that program are expected to begin in 2028.</li><li>Following the BL1107 topical setback, Bausch + Lomb’s most advanced pharmaceutical programs are now the dual-action dry eye drop and BL1332 for ocular pain.&nbsp;</li></ul>&nbsp;Shares of Bausch + Lomb (BLCO) fell 4% after hours on Thursday after the company said that its experimental glaucoma treatment BL1107 failed to improve vision in a mid-stage clinical trial, prompting the company to stop development of the drug as a daily eye drop.<h2 class="st-heading-2">Trial Results</h2>The randomized, double-masked study enrolled 159 patients with glaucoma or high eye pressure. After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores, which measure peripheral vision. Key secondary measures of vision improvement also fell short.The drug, however, did succeed in lowering eye pressure, meeting one secondary goal. Safety results were consistent with earlier studies, with no new concerns identified, the company said.Bausch + Lomb has decided not to move forward with BL1107 as a topical eye drop for glaucoma. The company noted that an earlier, smaller study had shown promising vision improvements, but the larger mid-stage trial did not confirm those findings.<h2 class="st-heading-2">Executives React</h2>“Success in drug development is based on a portfolio, not a single program,” said Yehia Hashad, Executive Vice President of R&amp;D and Chief Medical Officer. “Not every program will succeed, but every study helps us make smarter decisions.”Following the BL1107 topical setback, Bausch + Lomb’s most advanced pharmaceutical programs are now the dual-action dry eye drop and BL1332 for ocular pain, both with data readouts expected in the second half of 2026.Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant version of the same drug candidate for geographic atrophy, an advanced form of dry age-related macular degeneration, the company said. Clinical trials for that program are expected to begin in 2028.<h2 class="st-heading-2">How Did BLCO Retail Traders React?</h2>On Stocktwits, retail sentiment around BLCO stock stayed within the ‘neutral’ territory while message volume fell from ‘high’ to ‘normal’ levels.A Stocktwits user dismissed the company pipeline as the “worst.”<stembedurl>https://www.stocktwits.com/TickrTalk0007/message/658547774</stembedurl>Another termed the Thursday announcement a “clean negative readout.”<stembedurl>https://www.stocktwits.com/OttoReed328/message/658705745</stembedurl><a href="https://stocktwits.com/symbol/BLCO">BLCO stock</a> has fallen 2% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-chief-elon-musk-says-anthropic-is-clear-ai-leader-vows-not-to-sabotage-compute-deal-despite-rivalry/cZmYODsR7nC">SpaceX Chief Elon Musk Says Anthropic Is ‘Clear AI Leader’ — Vows Not To Sabotage Compute Deal Despite Rivalry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of eye health company Bausch Lomb Corporation is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study. 

Bausch + Lomb Corp.

Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Feed

News

Sentiment

Earnings

Fundamentals

Info

BLCO News